{"id":"W4304084160","doi":"10.1016/j.annonc.2022.09.159","title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; University of Illinois at Urbana-Champaign; National Institutes of Health; Karolinska Institutet; Clovis Oncology; National Institute for Health and Care Research; Seagen; Cilag; Puma Biotechnology; NRG Oncology; Les Laboratories Pierre Fabre; Institut Bergonié; Amgen; Rush University; University of Pennsylvania; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; School of Medicine, Indiana University; European Commission; Sanofi; Genomic Health; Ochsner Health; MSD; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Placebo; Hazard ratio; Breast cancer; Confidence interval; Cancer; Pathology; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003075093,0.001118322,0.001970916,0.0002702487,0.0002858786,0.001040233,0.0007080788,0.0009529863,0.002319061],"category_scores_gemma":[0.002174941,0.0005142424,0.002049236,0.0002596727,0.0007809515,0.0006114746,0.0005409378,0.002266372,0.0003425115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000730415,"about_ca_system_score_gemma":0.001256403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005127332,"about_ca_topic_score_gemma":0.001409276,"domain_scores_codex":[0.999015,0.0006039062,0.00005401434,0.0001276304,0.00006729614,0.0001320654],"domain_scores_gemma":[0.9989054,0.000262889,0.000356339,0.00009231933,0.00006238506,0.0003206291],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9800984,0.002646885,0.00279846,0.0002457963,0.0006636032,0.00002716938,0.00003099862,0.0004237086,0.00165509,0.00006064595,0.0006392426,0.01071],"study_design_scores_gemma":[0.9061911,0.08241545,0.008626021,0.0000495813,0.0007777688,0.00005755043,0.00002278297,0.0005575832,0.0004089964,0.0001359474,0.0007452275,0.00001192938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938304,0.002747786,0.0002803431,0.0004053595,0.0002680342,0.0008561442,0.0004859168,0.00003475257,0.001091416],"genre_scores_gemma":[0.992332,0.001462702,0.0006820057,0.0008399188,0.0003519467,0.001678789,0.001204346,0.0000109635,0.001437442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003075093,"threshold_uncertainty_score":0.01626283,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03810809554894744,"score_gpt":0.3551060294228056,"score_spread":0.3169979338738582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}